The MHRA Central Alerting System has issued two alerts warning that aminophylline tablets and morphine sulphate prolonged release granules for oral suspension are both being discontinued.
Aminophylline (Phyllocontin®) modified release tablets are being discontinued in both the 225mg and 350mg strengths. Remaining supplies in the distribution chain are expected to be exhausted by early April 2021. Theophylline (Uniphyllin®) tablets remain available and may provide a suitable alternative or inhaled therapies could be reviewed and optimised.
Morphine sulphate (MST Continus®) prolonged release granules for oral suspension are currently available in 20mg, 30mg, 60mg, 100mg and 200mg strengths. All strengths are being permanently discontinued during 2021 due to difficulty sourcing a key excipient. The alerts notes that alternative morphine presentations, both prolonged release and immediate release, remain available and will be able to support increased demand. The full document contains specific advice on which products can be opened and taken with food in the case of swallowing difficulties or via gastric or gastrostomy tubes.
Action: Clinicians should be aware of these products being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed these products to allow a review and arrangements made to identify suitable alternatives.
|« CKS Updates - February 2021||SMC Update - March 2021 »|